| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
PDE7A 2.1 μM (IC50)
PDE7-IN-2 specifically targets the phosphodiesterase 7 (PDE7) enzyme, a member of the cyclic nucleotide phosphodiesterase family. By inhibiting PDE7, it prevents the breakdown of the secondary messenger cyclic AMP (cAMP), leading to increased intracellular cAMP levels. This modulation of cAMP pathways is implicated in various physiological processes, including immune cell function and neuronal signaling, making it a target for Parkinson's disease research. |
|---|---|
| ln Vitro |
In vitro, PDE7-IN-2 demonstrates potent and selective inhibition of PDE7, with a reported IC50 of 2.1 microM. This activity is typically assessed in cell-free enzymatic assays. By inhibiting PDE7, the compound is used as a tool to study the downstream effects of cAMP elevation on cellular functions such as inflammation, proliferation, and survival in cultured cells, particularly those of the immune and central nervous systems.
|
| ln Vivo |
In vivo, the activity of PDE7-IN-2 has been explored primarily in preclinical models of Parkinson's disease. As a PDE7 inhibitor, it is hypothesized to have neuroprotective and anti-inflammatory effects. While detailed published in vivo data is limited, PDE7-IN-2 is available for research into neurological disorders, with studies showing the potential for PDE7 inhibitors to modulate movement and cognitive functions in animal models through cAMP-mediated pathways.
|
| Enzyme Assay |
PDE7-IN-2 is used in non-cellular in vitro assays to determine its inhibitory potency against the PDE7 enzyme. A typical protocol involves using a purified recombinant PDE7 enzyme. The compound is dissolved in DMSO to prepare a stock solution and then diluted in an assay buffer. The enzyme is incubated with the compound and a fluorescent or radiolabeled cAMP substrate. After incubation, the reaction is stopped, and the amount of hydrolyzed product (e.g., AMP) is measured, allowing for the calculation of the half-maximal inhibitory concentration (IC50).
|
| Cell Assay |
For in vitro cellular experiments, PDE7-IN-2 is dissolved in DMSO and further diluted in cell culture medium to the desired working concentration (typically 0.1-10 uM). Cells of interest (e.g., neuronal cell lines like SH-SY5Y or microglial cells) are seeded in multi-well plates and treated with the compound. After a defined incubation period (e.g., 24-48 hours), cellular effects are assessed. These can include measuring intracellular cAMP levels, cell viability (via MTT assay), or the expression of inflammatory markers via qPCR or ELISA.
|
| Animal Protocol |
For in vivo animal studies, PDE7-IN-2 is typically administered to rodents to evaluate its effects in models of Parkinson's disease. The compound is often formulated in a vehicle such as 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline or other suitable solvents. Administration routes may include intraperitoneal (i.p.) injection or oral gavage at specified doses. Following treatment, animals are subjected to behavioral tests (e.g., rotarod, open field) and their brains are harvested for biochemical and immunohistochemical analysis.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic (PK) parameters for PDE7-IN-2 are not extensively published in standard commercial documentation. As a research compound, its absorption, distribution, metabolism, and excretion (ADME) profile would be expected to be studied in the context of preclinical development. For in vivo use, the compound is typically formulated in a vehicle such as 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline to ensure adequate bioavailability.
|
| Toxicity/Toxicokinetics |
The toxicological profile of PDE7-IN-2 is not extensively detailed in public data sources. As a research chemical, it should be handled with standard laboratory precautions, including the use of personal protective equipment (PPE) such as gloves, lab coats, and safety glasses. Appropriate procedures should be followed to avoid direct contact with skin or eyes, and to prevent inhalation of dust or aerosolized particles. The compound is for research use only and not intended for human consumption.
|
| References |
[1]. García AM, wt, al. Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. J Med Chem. 2014 Oct 23;57(20):8590-607.
|
| Additional Infomation |
PDE7-IN-2 is not an approved drug but is a research-only biochemical tool. It is used for laboratory research purposes to study the biological role of phosphodiesterase 7 (PDE7). Its primary application is in the study of neurological disorders, specifically Parkinson's disease, where it is used to investigate the effects of PDE7 inhibition on motor function, neuroinflammation, and neuroprotection. It is a valuable tool for target validation and drug discovery.
|
| Molecular Formula |
C14H11CLN2O3S
|
|---|---|
| Molecular Weight |
322.77
|
| Exact Mass |
322.018
|
| CAS # |
107522-19-0
|
| PubChem CID |
101886690
|
| Appearance |
White to light yellow solid powder
|
| LogP |
4.954
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
391
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)NC1=CC=CC=C1SC2=C(C=CC(=C2)Cl)[N+](=O)[O-]
|
| InChi Key |
LAFNJWWMXIXPJF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H11ClN2O3S/c1-9(18)16-11-4-2-3-5-13(11)21-14-8-10(15)6-7-12(14)17(19)20/h2-8H,1H3,(H,16,18)
|
| Chemical Name |
N-[2-(5-chloro-2-nitrophenyl)sulfanylphenyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0982 mL | 15.4909 mL | 30.9818 mL | |
| 5 mM | 0.6196 mL | 3.0982 mL | 6.1964 mL | |
| 10 mM | 0.3098 mL | 1.5491 mL | 3.0982 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
